Menu Search
Equities

Human Metabolome Technologies Inc

6090:TYO

Human Metabolome Technologies Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)602.00
  • Today's Change-2.00 / -0.33%
  • Shares traded4.90k
  • 1 Year change-10.42%
  • Beta1.3706
Data delayed at least 20 minutes, as of Nov 22 2024 06:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Human Metabolome Technologies Inc had net income fall -14.88% from 285.76m to 243.25m despite a 3.57% increase in revenues from 1.30bn to 1.35bn. An increase in the cost of goods sold as a percentage of sales from 33.83% to 35.40% was a component in the falling net income despite rising revenues.
Gross margin65.13%
Net profit margin17.77%
Operating margin18.23%
Return on assets11.18%
Return on equity14.18%
Return on investment14.00%
More ▼

Cash flow in JPYView more

In 2024, Human Metabolome Technologies Inc increased its cash reserves by 7.95%, or 131.72m. The company earned 236.80m from its operations for a Cash Flow Margin of 17.60%. In addition the company used 32.44m on investing activities and also paid 73.15m in financing cash flows.
Cash flow per share59.04
Price/Cash flow per share10.24
Book value per share306.43
Tangible book value per share303.67
More ▼

Balance sheet in JPYView more

Human Metabolome Technologies Inc appears to have a strong balance sheet and has grown its cash reserves consistently over the last four years to total 1.79bn. In fact, 0.50% of the value of Human Metabolome Technologies Inc shares can be attributed to this cash.
Current ratio3.86
Quick ratio3.73
Total debt/total equity0.1221
Total debt/total capital0.1088
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.